This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Neuroendocrine Tumors or Heart Failure
and you are
between 21 and 85
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The goal of this proposal is to produce and test high specific activity Ultratrace iobenguane I 123 in normal human volunteers.

Provided treatments

  • Drug: no carrier added metaiodobenzylguanidine
Tris trial is registered with FDA with number: NCT01730417. The sponsor of the trial is Bennett Chin and it is looking for 12 volunteers for the current phase.
Official trial title:
Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG-Nanodosing: the Path to Higher Sensitivity and Lower Toxicity Radiopharmaceuticals